Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
2.37
Oct 22 • 3:59 PM ET Dollar change+0.02 Percentage change(0.85%)
Aftermarket Close
2.34
Aftermarket • 5:00 PM ET Dollar change-0.03 Percentage change(-1.11%)
Index
RUT
Market Cap
709.49M
Enterprise Value
618.54M
Income
-211.82M
Sales
0.00M
Book/sh
0.52
Cash/sh
0.55
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
142
IPO
Feb 04, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
4.59
P/C
4.31
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.38
Current Ratio
1.38
Debt/Eq
0.48
LT Debt/Eq
0.38
Option/Short
Yes / Yes
EPS (ttm)
-0.76
EPS next Y
-0.59
EPS next Q
-0.15
EPS this Y
28.65%
EPS next Y
13.71%
EPS next 5Y
14.37%
EPS past 3/5Y
12.33% 8.72%
Sales past 3/5Y
- -
EPS Y/Y TTM
28.46%
Sales Y/Y TTM
-
EPS Q/Q
45.30%
Sales Q/Q
-
Insider Own
37.61%
Insider Trans
0.00%
Inst Own
50.96%
Inst Trans
0.94%
ROA
-53.41%
ROE
-152.87%
ROIC
-99.07%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-10.39%
SMA50
-25.65%
SMA200
-31.44%
Trades
Shs Outstand
299.31M
Shs Float
186.78M
52W High
5.90 -59.83%
52W Low
2.22 6.76%
Volatility
7.08% 6.37%
ATR (14)
0.18
RSI (14)
33.33
Beta
2.29
Rel Volume
0.76
Avg Volume
3.21M
Volume
2,424,304
Perf Week
-4.24%
Perf Month
-23.05%
Perf Quarter
-25.47%
Perf Half Y
-31.10%
Perf YTD
-41.77%
Perf Year
-56.91%
Perf 3Y
-22.55%
Perf 5Y
-88.19%
Perf 10Y
-
Prev Close
2.35
Price
2.37
Change %
0.85%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PATEL DHAVALKUMAR DHIRAJLALEVP, Chief Scientific OfficerAug 26 '26Option Exercise0.00125,0000224,510Aug 27 04:21 PM
Harr StevePresident & CEOMar 07 '26Option Exercise0.0050,00007,968,596Mar 10 04:16 PM
Harr StevePresident & CEOMar 06 '26Option Exercise0.0041,66607,918,596Mar 10 04:16 PM
Wyrick Susan D.See RemarksMar 07 '26Option Exercise0.003,2500200,583Mar 10 04:15 PM
Wyrick Susan D.See RemarksMar 06 '26Option Exercise0.0010,4160197,333Mar 10 04:15 PM
Wyrick Susan D.See RemarksMar 02 '26Option Exercise0.001,5250187,408Mar 04 04:17 PM
Wyrick Susan D.See RemarksJan 02 '26Option Exercise0.007,5000188,290Jan 06 04:18 PM
Wyrick Susan D.See RemarksDec 13 '25Option Exercise0.003,4000181,663Dec 16 04:16 PM
Wyrick Susan D.See RemarksDec 03 '25Option Exercise0.0010,0000180,828Dec 05 05:04 PM
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.
PresidentDr. Steven D. Harr M.D.
Executive VP & CFOMr. Brian D. Piper M.B.A.
TreasurerMs. Susan Wyrick
Executive VP & Chief Technical OfficerMr. Snehal Patel
Ph.D.Dr. Dhavalkumar D. Patel M.D.